The market research report includes easily comparable data on industry value, volume, key market segments and industry share, plus full 5 year industry forecasts . It examines future problems, innovations and areas of market opportunities within the industry .

What's Included In This Report?


* Contains detailed market figures (value, volume and segmentation)


* Provides textual analysis of the market 's prospects, key competitors and profiles of the main industry players


* Incorporates in-depth environment and competition analysis and scorecards (substitution threats, new entrants, bargaining power …)


* Compares data from the US, Canada, Germany, France, UK, Italy, Russia and Japan, alongside individual chapters on each country. .


* Includes a 5 year Market forecast

Key Market Facts

The G8 Pharmaceuticals industry grew by 3.3% between 2006 and 2010 to reach a value of USD 525.3 billion

In 2015, the industry is projection to have a value of USD 632.9 billion, a rise of 3.8% from 2009.

The US is expected to lead the Pharmaceuticals market in the G8 nations with a value of USD 344.7 billon in 2014

This Report Will Support Your Decision Making Process


* Anticipate Industry trends and developments


* Feed your decision making process


* Make your presentation and marketing materials more valuable


* Save time

Market Definition

The pharmaceuticals industry consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Industry values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this market research report have been calculated at constant 2009 annual average exchange rates.

Table Of Contents

TABLE OF CONTENTS
ABOUT DATAMONITOR 2
INTRODUCTION 22
What's included this report? 22
Who is the target reader? 22
Definitions 22
GROUP OF EIGHT (G8) PHARMACEUTICALS INDUSTRY OUTLOOK 23
PHARMACEUTICALS IN CANADA 30
MARKET OVERVIEW 30
MARKET VALUE 31
MARKET SEGMENTATION I 32
MARKET SEGMENTATION II 33
MARKET SHARE 34
FIVE FORCES ANALYSIS 35
LEADING COMPANIES 43
MARKET FORECASTS 56
MACROECONOMIC INDICATORS 58
PHARMACEUTICALS IN FRANCE 60
MARKET OVERVIEW 60
MARKET VALUE 61
MARKET SEGMENTATION I 62
MARKET SEGMENTATION II 63
MARKET SHARE 64
FIVE FORCES ANALYSIS 65
LEADING COMPANIES 74
MARKET FORECASTS 91
MACROECONOMIC INDICATORS 93
PHARMACEUTICALS IN GERMANY 95
MARKET OVERVIEW 95
MARKET VALUE 96
MARKET SEGMENTATION I 97
MARKET SEGMENTATION II 98
MARKET SHARE 99
FIVE FORCES ANALYSIS 100
LEADING COMPANIES 109
MARKET FORECASTS 127
MACROECONOMIC INDICATORS 129
PHARMACEUTICALS IN ITALY 131
MARKET OVERVIEW 131
MARKET VALUE 132
MARKET SEGMENTATION I 133
MARKET SEGMENTATION II 134
MARKET SHARE 135
FIVE FORCES ANALYSIS 136
LEADING COMPANIES 146
MARKET FORECASTS 160
MACROECONOMIC INDICATORS 162
PHARMACEUTICALS IN JAPAN 164
MARKET OVERVIEW 164
MARKET VALUE 165
MARKET SEGMENTATION I 166
MARKET SEGMENTATION II 167
MARKET SHARE 168
FIVE FORCES ANALYSIS 169
LEADING COMPANIES 179
MARKET FORECASTS 198
MACROECONOMIC INDICATORS 200
PHARMACEUTICALS IN RUSSIA 202
MARKET OVERVIEW 202
MARKET VALUE 203
MARKET SEGMENTATION I 204
MARKET SEGMENTATION II 205
MARKET SHARE 206
FIVE FORCES ANALYSIS 207
LEADING COMPANIES 216
MARKET FORECASTS 228
MACROECONOMIC INDICATORS 230
PHARMACEUTICALS IN THE UNITED KINGDOM 232
MARKET OVERVIEW 232
MARKET VALUE 233
MARKET SEGMENTATION I 234
MARKET SEGMENTATION II 235
MARKET SHARE 236
FIVE FORCES ANALYSIS 237
LEADING COMPANIES 248
MARKET FORECASTS 265
MACROECONOMIC INDICATORS 267
PHARMACEUTICALS IN THE UNITED STATES 269
MARKET OVERVIEW 269
MARKET VALUE 270
MARKET SEGMENTATION I 271
MARKET SEGMENTATION II 272
MARKET SHARE 273
FIVE FORCES ANALYSIS 274
LEADING COMPANIES 284
MARKET FORECASTS 307
MACROECONOMIC INDICATORS 309
APPENDIX 311
Data Research Methodology 311


Index of Tables
Data table 1: G8 pharmaceuticals market, revenue($m), 2006-15 24
Data table 2: G8 pharmaceuticals market, revenue by country ($m), 2006-10(e) 27
Data table 3: G8 pharmaceuticals market projection, revenue by country ($m), 2010-15 29
Data table 4: Canada pharmaceuticals market sales : USD billion, 2006-10(e) 31
Data table 5: Canada pharmaceuticals industry sector ation I:% share, by value, 2010(e) 32
Data table 6: Canada pharmaceuticals industry sector ation II: % share, by value, 2010(e) 33
Data table 7: Canada pharmaceuticals industry share: % share, by value, 2010(e) 34
Data table 8: Apotex, Inc.: key facts 43
Data table 9: AstraZeneca PLC: key facts 45
Data table 10: AstraZeneca PLC: key financials ($) 48
Data table 11: AstraZeneca PLC: key financial ratios 49
Data table 12: Johnson and Johnson: key facts 51
Data table 13: Johnson and Johnson: key financials ($) 53
Data table 14: Johnson and Johnson: key financial ratios 53
Data table 15: Canada pharmaceuticals market sales projection : USD billion, 2010-15 56
Data table 16: Canada size of population (million), 2006-10 58
Data table 17: Canada Gross Domestic Product (constant 2000 prices, USD billion), 2006-10 58
Data table 18: Canada Gross Domestic Product (current prices, USD billion), 2006-10 58
Data table 19: Canada inflation, 2006-10 59
Data table 20: Canada consumer price index (absolute), 2006-10 59
Data table 21: Canada exchange rate, 2006-10 59
Data table 22: France pharmaceuticals market sales : USD billion, 2006-10(e) 61
Data table 23: France pharmaceuticals industry sector ation I:% share, by value, 2010(e) 62
Data table 24: France pharmaceuticals industry sector ation II: % share, by value, 2010(e) 63
Data table 25: France pharmaceuticals industry share: % share, by value, 2010(e) 64
Data table 26: AstraZeneca PLC: key facts 74
Data table 27: AstraZeneca PLC: key financials ($) 77
Data table 28: AstraZeneca PLC: key financial ratios 77
Data table 29: GlaxoSmithKline Plc: key facts 80
Data table 30: GlaxoSmithKline Plc: key financials ($) 82
Data table 31: GlaxoSmithKline Plc: key financials (£) 83
Data table 32: GlaxoSmithKline Plc: key financial ratios 83
Data table 33: Pfizer Inc.: key facts 86
Data table 34: Pfizer Inc.: key financials ($) 88
Data table 35: Pfizer Inc.: key financial ratios 88
Data table 36: France pharmaceuticals market sales projection : USD billion, 2010-15 91
Data table 37: France size of population (million), 2006-10 93
Data table 38: France Gross Domestic Product (constant 2000 prices, USD billion), 2006-10 93
Data table 39: France Gross Domestic Product (current prices, USD billion), 2006-10 93
Data table 40: France inflation, 2006-10 94
Data table 41: France consumer price index (absolute), 2006-10 94
Data table 42: France exchange rate, 2006-10 94
Data table 43: Germany pharmaceuticals market sales : USD billion, 2006-10(e) 96
Data table 44: Germany pharmaceuticals industry sector ation I:% share, by value, 2010(e) 97
Data table 45: Germany pharmaceuticals industry sector ation II: % share, by value, 2010(e) 98
Data table 46: Germany pharmaceuticals industry share: % share, by value, 2010(e) 99
Data table 47: GlaxoSmithKline Plc: key facts 109
Data table 48: GlaxoSmithKline Plc: key financials ($) 112
Data table 49: GlaxoSmithKline Plc: key financials (£) 113
Data table 50: GlaxoSmithKline Plc: key financial ratios 113
Data table 51: Novartis AG: key facts 116
Data table 52: Novartis AG: key financials ($) 119
Data table 53: Novartis AG: key financial ratios 119
Data table 54: Pfizer Inc.: key facts 122
Data table 55: Pfizer Inc.: key financials ($) 124
Data table 56: Pfizer Inc.: key financial ratios 124
Data table 57: Germany pharmaceuticals market sales projection : USD billion, 2010-15 127
Data table 58: Germany size of population (million), 2006-10 129
Data table 59: Germany Gross Domestic Product (constant 2000 prices, USD billion), 2006-10 129
Data table 60: Germany Gross Domestic Product (current prices, USD billion), 2006-10 129
Data table 61: Germany inflation, 2006-10 130
Data table 62: Germany consumer price index (absolute), 2006-10 130
Data table 63: Germany exchange rate, 2006-10 130
Data table 64: Italy pharmaceuticals market sales : USD billion, 2006-10(e) 132
Data table 65: Italy pharmaceuticals industry sector ation I:% share, by value, 2010(e) 133
Data table 66: Italy pharmaceuticals industry sector ation II: % share, by value, 2010(e) 134
Data table 67: Italy pharmaceuticals industry share: % share, by value, 2010(e) 135
Data table 68: GlaxoSmithKline Plc: key facts 146
Data table 69: GlaxoSmithKline Plc: key financials ($) 149
Data table 70: GlaxoSmithKline Plc: key financials (£) 150
Data table 71: GlaxoSmithKline Plc: key financial ratios 150
Data table 72: Menarini Group: key facts 153
Data table 73: Pfizer Inc.: key facts 155
Data table 74: Pfizer Inc.: key financials ($) 157
Data table 75: Pfizer Inc.: key financial ratios 157
Data table 76: Italy pharmaceuticals market sales projection : USD billion, 2010-15 160
Data table 77: Italy size of population (million), 2006-10 162
Data table 78: Italy Gross Domestic Product (constant 2000 prices, USD billion), 2006-10 162
Data table 79: Italy Gross Domestic Product (current prices, USD billion), 2006-10 162
Data table 80: Italy inflation, 2006-10 163
Data table 81: Italy consumer price index (absolute), 2006-10 163
Data table 82: Italy exchange rate, 2006-10 163
Data table 83: Japan pharmaceuticals market sales : USD billion, 2006-10(e) 165
Data table 84: Japan pharmaceuticals industry sector ation I:% share, by value, 2010(e) 166
Data table 85: Japan pharmaceuticals industry sector ation II: % share, by value, 2010(e) 167
Data table 86: Japan pharmaceuticals industry share: % share, by value, 2010(e) 168
Data table 87: Astellas Pharma Inc.: key facts 179
Data table 88: Astellas Pharma Inc.: key financials ($) 181
Data table 89: Astellas Pharma Inc.: key financials (Â¥) 181
Data table 90: Astellas Pharma Inc.: key financial ratios 182
Data table 91: Daiichi Sankyo Co., Ltd.: key facts 184
Data table 92: Daiichi Sankyo Co., Ltd.: key financials ($) 185
Data table 93: Daiichi Sankyo Co., Ltd.: key financials (Â¥) 185
Data table 94: Daiichi Sankyo Co., Ltd.: key financial ratios 186
Data table 95: Pfizer Inc.: key facts 188
Data table 96: Pfizer Inc.: key financials ($) 190
Data table 97: Pfizer Inc.: key financial ratios 190
Data table 98: Sanofi-Aventis SA: key facts 193
Data table 99: Sanofi-Aventis SA: key financials ($) 194
Data table 100: Sanofi-Aventis SA: key financials (€) 195
Data table 101: Sanofi-Aventis SA: key financial ratios 195
Data table 102: Japan pharmaceuticals market sales projection : USD billion, 2010-15 198
Data table 103: Japan size of population (million), 2006-10 200
Data table 104: Japan Gross Domestic Product (constant 2000 prices, USD billion), 2006-10 200
Data table 105: Japan Gross Domestic Product (current prices, USD billion), 2006-10 200
Data table 106: Japan inflation, 2006-10 201
Data table 107: Japan consumer price index (absolute), 2006-10 201
Data table 108: Japan exchange rate, 2006-10 201
Data table 109: Russia pharmaceuticals market sales : USD billion, 2006-10(e) 203
Data table 110: Russia pharmaceuticals industry sector ation I:% share, by value, 2010(e) 204
Data table 111: Russia pharmaceuticals industry sector ation II: % share, by value, 2010(e) 205
Data table 112: Russia pharmaceuticals industry share: % share, by value, 2010(e) 206
Data table 113: Novartis AG: key facts 216
Data table 114: Novartis AG: key financials ($) 219
Data table 115: Novartis AG: key financial ratios 219
Data table 116: Pharmstandard: key facts 222
Data table 117: Sanofi-Aventis SA: key facts 224
Data table 118: Sanofi-Aventis SA: key financials ($) 225
Data table 119: Sanofi-Aventis SA: key financials (€) 225
Data table 120: Sanofi-Aventis SA: key financial ratios 226
Data table 121: Russia pharmaceuticals market sales projection : USD billion, 2010-15 228
Data table 122: Russia size of population (million), 2006-10 230
Data table 123: Russia Gross Domestic Product (constant 2000 prices, USD billion), 2006-10 230
Data table 124: Russia Gross Domestic Product (current prices, USD billion), 2006-10 230
Data table 125: Russia inflation, 2006-10 231
Data table 126: Russia consumer price index (absolute), 2006-10 231
Data table 127: Russia exchange rate, 2006-10 231
Data table 128: United Kingdom pharmaceuticals market sales : USD billion, 2006-10(e) 233
Data table 129: United Kingdom pharmaceuticals industry sector ation I:% share, by value, 2010(e) 234
Data table 130: United Kingdom pharmaceuticals industry sector ation II: % share, by value, 2010(e) 235
Data table 131: United Kingdom pharmaceuticals industry share: % share, by value, 2010(e) 236
Data table 132: AstraZeneca PLC: key facts 248
Data table 133: AstraZeneca PLC: key financials ($) 251
Data table 134: AstraZeneca PLC: key financial ratios 252
Data table 135: GlaxoSmithKline Plc: key facts 254
Data table 136: GlaxoSmithKline Plc: key financials ($) 257
Data table 137: GlaxoSmithKline Plc: key financials (£) 257
Data table 138: GlaxoSmithKline Plc: key financial ratios 257
Data table 139: Pfizer Inc.: key facts 260
Data table 140: Pfizer Inc.: key financials ($) 262
Data table 141: Pfizer Inc.: key financial ratios 262
Data table 142: United Kingdom pharmaceuticals market sales projection : USD billion, 2010-15 265
Data table 143: United Kingdom size of population (million), 2006-10 267
Data table 144: United Kingdom Gross Domestic Product (constant 2000 prices, USD billion), 2006-10 267
Data table 145: United Kingdom Gross Domestic Product (current prices, USD billion), 2006-10 267
Data table 146: United Kingdom inflation, 2006-10 268
Data table 147: United Kingdom consumer price index (absolute), 2006-10 268
Data table 148: United Kingdom exchange rate, 2006-10 268
Data table 149: United States pharmaceuticals market sales : USD billion, 2006-10(e) 270
Data table 150: United States pharmaceuticals industry sector ation I:% share, by value, 2010(e) 271
Data table 151: United States pharmaceuticals industry sector ation II: % share, by value, 2010(e) 272
Data table 152: United States pharmaceuticals industry share: % share, by value, 2010(e) 273
Data table 153: GlaxoSmithKline Plc: key facts 284
Data table 154: GlaxoSmithKline Plc: key financials ($) 287
Data table 155: GlaxoSmithKline Plc: key financials (£) 288
Data table 156: GlaxoSmithKline Plc: key financial ratios 288
Data table 157: Johnson and Johnson: key facts 291
Data table 158: Johnson and Johnson: key financials ($) 293
Data table 159: Johnson and Johnson: key financial ratios 293
Data table 160: Merck and Co., Inc.: key facts 296
Data table 161: Merck and Co., Inc.: key financials ($) 299
Data table 162: Merck and Co., Inc.: key financial ratios 299
Data table 163: Pfizer Inc.: key facts 302
Data table 164: Pfizer Inc.: key financials ($) 304
Data table 165: Pfizer Inc.: key financial ratios 304
Data table 166: United States pharmaceuticals market sales projection : USD billion, 2010-15 307
Data table 167: United States size of population (million), 2006-10 309
Data table 168: United States Gross Domestic Product (constant 2000 prices, USD billion), 2006-10 309
Data table 169: United States Gross Domestic Product (current prices, USD billion), 2006-10 309
Data table 170: United States inflation, 2006-10 310
Data table 171: United States consumer price index (absolute), 2006-10 310
Data table 172: United States exchange rate, 2006-10 310

Index of Figures
Chart 1: G8 pharmaceuticals market, revenue($m), 2006-15 23
Chart 2: G8 Pharmaceuticals market, revenue by country (%), 2010 25
Chart 3: G8 pharmaceuticals market, revenue by country ($m), 2006-10 26
Chart 4: G8 pharmaceuticals market projection, revenue by country ($m), 2010-15 28
Chart 5: Canada pharmaceuticals market sales : USD billion, 2006-10(e) 31
Chart 6: Canada pharmaceuticals industry sector ation I:% share, by value, 2010(e) 32
Chart 7: Canada pharmaceuticals industry sector ation II: % share, by value, 2010(e) 33
Chart 8: Canada pharmaceuticals industry share: % share, by value, 2010(e) 34
Chart 9: Forces driving competition in the pharmaceuticals industry in Canada, 2010 35
Chart 10: Drivers of buyer power in the pharmaceuticals industry in Canada, 2010 36
Chart 11: Drivers of supplier power in the pharmaceuticals industry in Canada, 2010 37
Chart 12: Factors influencing the likelihood of new entrants in the pharmaceuticals industry in Canada, 2010 39
Chart 13: Factors influencing the threat of substitutes in the pharmaceuticals industry in Canada, 2010 41
Chart 14: Drivers of degree of rivalry in the pharmaceuticals industry in Canada, 2010 42
Chart 15: AstraZeneca PLC: revenues and profitability 49
Chart 16: AstraZeneca PLC: assets and liabilities 50
Chart 17: Johnson and Johnson: revenues and profitability 54
Chart 18: Johnson and Johnson: assets and liabilities 55
Chart 19: Canada pharmaceuticals market sales projection : USD billion, 2010-15 57
Chart 20: France pharmaceuticals market sales : USD billion, 2006-10(e) 61
Chart 21: France pharmaceuticals industry sector ation I:% share, by value, 2010(e) 62
Chart 22: France pharmaceuticals industry sector ation II: % share, by value, 2010(e) 63
Chart 23: France pharmaceuticals industry share: % share, by value, 2010(e) 64
Chart 24: Forces driving competition in the pharmaceuticals industry in France, 2010 65
Chart 25: Drivers of buyer power in the pharmaceuticals industry in France, 2010 67
Chart 26: Drivers of supplier power in the pharmaceuticals industry in France, 2010 68
Chart 27: Factors influencing the likelihood of new entrants in the pharmaceuticals industry in France, 2010 70
Chart 28: Factors influencing the threat of substitutes in the pharmaceuticals industry in France, 2010 72
Chart 29: Drivers of degree of rivalry in the pharmaceuticals industry in France, 2010 73
Chart 30: AstraZeneca PLC: revenues and profitability 78
Chart 31: AstraZeneca PLC: assets and liabilities 79
Chart 32: GlaxoSmithKline Plc: revenues and profitability 84
Chart 33: GlaxoSmithKline Plc: assets and liabilities 85
Chart 34: Pfizer Inc.: revenues and profitability 89
Chart 35: Pfizer Inc.: assets and liabilities 90
Chart 36: France pharmaceuticals market sales projection : USD billion, 2010-15 92
Chart 37: Germany pharmaceuticals market sales : USD billion, 2006-10(e) 96
Chart 38: Germany pharmaceuticals industry sector ation I:% share, by value, 2010(e) 97
Chart 39: Germany pharmaceuticals industry sector ation II: % share, by value, 2010(e) 98
Chart 40: Germany pharmaceuticals industry share: % share, by value, 2010(e) 99
Chart 41: Forces driving competition in the pharmaceuticals industry in Germany, 2010 100
Chart 42: Drivers of buyer power in the pharmaceuticals industry in Germany, 2010 102
Chart 43: Drivers of supplier power in the pharmaceuticals industry in Germany, 2010 103
Chart 44: Factors influencing the likelihood of new entrants in the pharmaceuticals industry in Germany, 2010 105
Chart 45: Factors influencing the threat of substitutes in the pharmaceuticals industry in Germany, 2010 107
Chart 46: Drivers of degree of rivalry in the pharmaceuticals industry in Germany, 2010 108
Chart 47: GlaxoSmithKline Plc: revenues and profitability 114
Chart 48: GlaxoSmithKline Plc: assets and liabilities 115
Chart 49: Novartis AG: revenues and profitability 120
Chart 50: Novartis AG: assets and liabilities 121
Chart 51: Pfizer Inc.: revenues and profitability 125
Chart 52: Pfizer Inc.: assets and liabilities 126
Chart 53: Germany pharmaceuticals market sales projection : USD billion, 2010-15 128
Chart 54: Italy pharmaceuticals market sales : USD billion, 2006-10(e) 132
Chart 55: Italy pharmaceuticals industry sector ation I:% share, by value, 2010(e) 133
Chart 56: Italy pharmaceuticals industry sector ation II: % share, by value, 2010(e) 134
Chart 57: Italy pharmaceuticals industry share: % share, by value, 2010(e) 135
Chart 58: Forces driving competition in the pharmaceuticals industry in Italy, 2010 136
Chart 59: Drivers of buyer power in the pharmaceuticals industry in Italy, 2010 138
Chart 60: Drivers of supplier power in the pharmaceuticals industry in Italy, 2010 140
Chart 61: Factors influencing the likelihood of new entrants in the pharmaceuticals industry in Italy, 2010 142
Chart 62: Factors influencing the threat of substitutes in the pharmaceuticals industry in Italy, 2010 144
Chart 63: Drivers of degree of rivalry in the pharmaceuticals industry in Italy, 2010 145
Chart 64: GlaxoSmithKline Plc: revenues and profitability 151
Chart 65: GlaxoSmithKline Plc: assets and liabilities 152
Chart 66: Pfizer Inc.: revenues and profitability 158
Chart 67: Pfizer Inc.: assets and liabilities 159
Chart 68: Italy pharmaceuticals market sales projection : USD billion, 2010-15 161
Chart 69: Japan pharmaceuticals market sales : USD billion, 2006-10(e) 165
Chart 70: Japan pharmaceuticals industry sector ation I:% share, by value, 2010(e) 166
Chart 71: Japan pharmaceuticals industry sector ation II: % share, by value, 2010(e) 167
Chart 72: Japan pharmaceuticals industry share: % share, by value, 2010(e) 168
Chart 73: Forces driving competition in the pharmaceuticals industry in Japan, 2010 169
Chart 74: Drivers of buyer power in the pharmaceuticals industry in Japan, 2010 171
Chart 75: Drivers of supplier power in the pharmaceuticals industry in Japan, 2010 173
Chart 76: Factors influencing the likelihood of new entrants in the pharmaceuticals industry in Japan, 2010 175
Chart 77: Factors influencing the threat of substitutes in the pharmaceuticals industry in Japan, 2010 177
Chart 78: Drivers of degree of rivalry in the pharmaceuticals industry in Japan, 2010 178
Chart 79: Astellas Pharma Inc.: revenues and profitability 182
Chart 80: Astellas Pharma Inc.: assets and liabilities 183
Chart 81: Daiichi Sankyo Co., Ltd.: revenues and profitability 186
Chart 82: Daiichi Sankyo Co., Ltd.: assets and liabilities 187
Chart 83: Pfizer Inc.: revenues and profitability 191
Chart 84: Pfizer Inc.: assets and liabilities 192
Chart 85: Sanofi-Aventis SA: revenues and profitability 196
Chart 86: Sanofi-Aventis SA: assets and liabilities 197
Chart 87: Japan pharmaceuticals market sales projection : USD billion, 2010-15 199
Chart 88: Russia pharmaceuticals market sales : USD billion, 2006-10(e) 203
Chart 89: Russia pharmaceuticals industry sector ation I:% share, by value, 2010(e) 204
Chart 90: Russia pharmaceuticals industry sector ation II: % share, by value, 2010(e) 205
Chart 91: Russia pharmaceuticals industry share: % share, by value, 2010(e) 206
Chart 92: Forces driving competition in the pharmaceuticals industry in Russia, 2010 207
Chart 93: Drivers of buyer power in the pharmaceuticals industry in Russia, 2010 208
Chart 94: Drivers of supplier power in the pharmaceuticals industry in Russia, 2010 210
Chart 95: Factors influencing the likelihood of new entrants in the pharmaceuticals industry in Russia, 2010 212
Chart 96: Factors influencing the threat of substitutes in the pharmaceuticals industry in Russia, 2010 214
Chart 97: Drivers of degree of rivalry in the pharmaceuticals industry in Russia, 2010 215
Chart 98: Novartis AG: revenues and profitability 220
Chart 99: Novartis AG: assets and liabilities 221
Chart 100: Sanofi-Aventis SA: revenues and profitability 226
Chart 101: Sanofi-Aventis SA: assets and liabilities 227
Chart 102: Russia pharmaceuticals market sales projection : USD billion, 2010-15 229
Chart 103: United Kingdom pharmaceuticals market sales : USD billion, 2006-10(e) 233
Chart 104: United Kingdom pharmaceuticals industry sector ation I:% share, by value, 2010(e) 234
Chart 105: United Kingdom pharmaceuticals industry sector ation II: % share, by value, 2010(e) 235
Chart 106: United Kingdom pharmaceuticals industry share: % share, by value, 2010(e) 236
Chart 107: Forces driving competition in the pharmaceuticals industry in the United Kingdom, 2010 237
Chart 108: Drivers of buyer power in the pharmaceuticals industry in the United Kingdom, 2010 239
Chart 109: Drivers of supplier power in the pharmaceuticals industry in the United Kingdom, 2010 241
Chart 110: Factors influencing the likelihood of new entrants in the pharmaceuticals industry in the United Kingdom, 2010 243
Chart 111: Factors influencing the threat of substitutes in the pharmaceuticals industry in the United Kingdom, 2010 245
Chart 112: Drivers of degree of rivalry in the pharmaceuticals industry in the United Kingdom, 2010 247
Chart 113: AstraZeneca PLC: revenues and profitability 252
Chart 114: AstraZeneca PLC: assets and liabilities 253
Chart 115: GlaxoSmithKline Plc: revenues and profitability 258
Chart 116: GlaxoSmithKline Plc: assets and liabilities 259
Chart 117: Pfizer Inc.: revenues and profitability 263
Chart 118: Pfizer Inc.: assets and liabilities 264
Chart 119: United Kingdom pharmaceuticals market sales projection : USD billion, 2010-15 266
Chart 120: United States pharmaceuticals market sales : USD billion, 2006-10(e) 270
Chart 121: United States pharmaceuticals industry sector ation I:% share, by value, 2010(e) 271
Chart 122: United States pharmaceuticals industry sector ation II: % share, by value, 2010(e) 272
Chart 123: United States pharmaceuticals industry share: % share, by value, 2010(e) 273
Chart 124: Forces driving competition in the pharmaceuticals industry in the United States, 2010 274
Chart 125: Drivers of buyer power in the pharmaceuticals industry in the United States, 2010 275
Chart 126: Drivers of supplier power in the pharmaceuticals industry in the United States, 2010 277
Chart 127: Factors influencing the likelihood of new entrants in the pharmaceuticals industry in the United States, 2010 279
Chart 128: Factors influencing the threat of substitutes in the pharmaceuticals industry in the United States, 2010 281
Chart 129: Drivers of degree of rivalry in the pharmaceuticals industry in the United States, 2010 283
Chart 130: GlaxoSmithKline Plc: revenues and profitability 289
Chart 131: GlaxoSmithKline Plc: assets and liabilities 290
Chart 132: Johnson and Johnson: revenues and profitability 294
Chart 133: Johnson and Johnson: assets and liabilities 295
Chart 134: Merck and Co., Inc.: revenues and profitability 300
Chart 135: Merck and Co., Inc.: assets and liabilities 301
Chart 136: Pfizer Inc.: revenues and profitability 305
Chart 137: Pfizer Inc.: assets and liabilities 306
Chart 138: United States pharmaceuticals market sales projection : USD billion, 2010-15 308

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • July 2014
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023 Summary GlobalData estimates that the total market size for the 7MM in 2013 was $12.3bn, comprised of $5.0bn in branded ...

Analysis of the Global Infectious Disease Diagnostics Market

Analysis of the Global Infectious Disease Diagnostics Market

  • $ 10 000
  • Industry report
  • September 2014
  • by Frost & Sullivan

Molecular Methods Present Significant Opportunities This deliverable provides research and analysis of the global infectious disease diagnostics market. It includes an in-depth analysis of revenue forecast ...

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

  • $ 6 995
  • Industry report
  • July 2014
  • by GBI Research

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation Summary Exceptionally Large and Innovative Pipeline The breast cancer pipeline is the largest in the pharmaceutical ...

Bcc Research Bitopertin Forecast

August 2014 $ 5 500

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.